Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336920 · ClinicalTrials.gov registry record · Phase 1
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
A Phase 1 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 3
- Study locations
NCT01336920 is a Phase 1 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma that has completed, run by University of Nebraska. The registered enrollment target is 15 participants, below the 106-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01336920, a Phase 1 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of carfilzomib in treating patients with relapsed or refractory T-cell lymphoma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- DRUG carfilzomib
Study Locations (3)
Georgia
- Emory University, Winship Cancer Institute - Atlanta
Nebraska
- University of Nebraska Medical Center - Omaha
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2011-06-21 |
| Est. Completion | 2018-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01336920
The ClinicalTrials.gov registry entry for NCT01336920 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (86% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which carfilzomib is the first listed.
NCT01336920 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Georgia, Nebraska, Texas.
Frequently Asked Questions
What is clinical trial NCT01336920 about?
NCT01336920 is a clinical study titled "Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma". This phase I trial studies the side effects and best dose of carfilzomib in treating patients with relapsed or refractory T-cell lymphoma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01336920?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2011-06-21. Estimated completion is 2018-03-01.
What conditions does trial NCT01336920 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma.
What interventions are being tested in trial NCT01336920?
The interventions under investigation include: carfilzomib (DRUG).
Who is sponsoring clinical trial NCT01336920?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01336920 being conducted?
This trial has 3 study locations across Georgia, Nebraska, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RECRUITING · Phase 1
-
Evaluate the Safety and Clinical Activity of HH2853
RECRUITING · Phase 1
-
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.